Siegfried Holding AG, trading over the counter as SGFEF, is a Switzerland-based contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1873 and headquartered in Zofingen, the company has grown from a regional chemical producer into a global partner for pharmaceutical and biotechnology firms. Over its more than 140-year history, Siegfried has expanded through strategic acquisitions and investments in research and production technologies to meet evolving industry needs.
The company’s core offerings include custom synthesis, process development and scale-up for small-molecule APIs, as well as commercial-scale API manufacturing. Siegfried also provides drug product services such as formulation development, clinical-trial manufacturing, fill-and-finish operations, blister packaging and secondary packaging. By integrating development and manufacturing capabilities under one roof, the firm aims to streamline supply chains, reduce time to market and ensure regulatory compliance for its customers worldwide.
Siegfried serves a diverse global customer base, supporting innovators, generic drug producers and niche biotech companies. Its manufacturing and development sites are located across Europe, North America and Asia, including facilities in Switzerland, Germany, the United States and China. This geographic footprint enables the company to offer flexible supply-chain solutions and responsive local service. Under the leadership of Chief Executive Officer Marco Mamone, Siegfried continues to invest in technological upgrades and capacity expansions to address growing demand for high-quality pharmaceutical manufacturing services.
AI Generated. May Contain Errors.